Those that follow Anteo know that one of their partners they have been working with has been called "POC1"
Below are a list of comparisons that has led some investors to believe "POC1" is indeed global giant Philips Healthcare.
Philips are currently developing a Handheld Point of Care device with the first test to be in the critical care market with a Troponin test.
Some of the comparisons that have led some Anteo investors towards thinking "POC1" being Philips :
- POC1 as a company with revenues of around $10bn in 2013, the same as what Philips reported
- ADO stating the initial application is in 'critical care - cardiac function' (same as Minicare)
- ADO saying the device has been six years in development (same timeline as Minicare)
- ADO stating the target time frame for launch is 2015, which is again coincidentally the same as Philips' device.
The thing that I really add value to was that before "POC1" was working with Anteo their device was not functioning properly and then already spent apparently tens of millions in development costs.
Anteo has now been working with POC1 for 12-18 months and have a working prototype. Anteo recently did a technology transfer for the Nanoparticles which are inside the disposable cartridge and are now working to optimise the performance of the biosensor.
Other than the potential value of what royalties Anteo could potentially earn - eg. A royalty on each test sold I look at the massive value this has for the whole point of care market of around $5billion. As a subset the Critical care market is worth around $1b pa with Troponin a large component of this. To date testing has been done in clinical laboratories.
As well the device itself "MINICARE" if that is who "POC1" is - Troponin is the first test of many others that can be used inside the Minicare device.
See below a very recent video from Philips on the Minicare device
I suggest doing some research on how Anteo can/could/has helped them with this device.
DISCLOSURE : THE AUTHOR HOLDS SHARES IN THIS COMPANY. THIS RESEARCH IS NOT A RECOMMENDATION TO BUY OR SELL SHARES IN THIS COMPANY. THE AUTHOR MAY AT ANY TIME BUY OR SELL SHARES WITHOUT NOTICE. PLEASE DO YOUR OWN RESEARCH